HBV preS2 transactivates FOXP3 expression in malignant hepatocytes

Liver International

Volumn 35, Issue 3, 2015, Pages 1087-1094

  Zhang, Xiaoning ^a   Gao, Lifen ^a   Liang, Xiaohong ^a   Guo, Min ^a   Wang, Rong ^a   Pan, Yingfang ^a   Liu, Peng ^a   Zhang, Feng ^a   Guo, Chun ^a   Zhu, Faliang ^a   Qu, Chunfeng ^b   Ma, Chunhong ^a  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Forkhead box protein 3; HBV preS2 protein; Hepatocellular carcinoma; Transcriptional regulation

Indexed keywords

PROTEIN PRES2; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; VIRUS PROTEIN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; HEPATITIS B SURFACE ANTIGEN; PRESURFACE PROTEIN 2, HEPATITIS B SURFACE ANTIGEN; PROTEIN PRECURSOR;

ARTICLE; BINDING SITE; CONTROLLED STUDY; GENETIC TRANSFECTION; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL; LIVER CELL CARCINOMA; LUCIFERASE ASSAY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSACTIVATION; UPREGULATION; WESTERN BLOTTING; CASE CONTROL STUDY; GENE EXPRESSION REGULATION; HEPATITIS B; HEPG2 CELL LINE; LIVER TUMOR; METABOLISM; PROMOTER REGION; TRANSCRIPTION INITIATION;

CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATOCYTES; HUMANS; LIVER NEOPLASMS; PROMOTER REGIONS, GENETIC; PROTEIN PRECURSORS; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTIONAL ACTIVATION;

EID: 84922605333     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12642     Document Type: Article

References (36)

1. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127(5 Suppl. 1): S5-16.
2. El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 2000; 160: 3227-30.
3. Montalto G, Cervello M, Giannitrapani L, et al. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann N Y Acad Sci 2002; 963: 13-20.
4. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118: 3030-44.
5. Brechot C, Pourcel C, Louise A, Rain B, Tiollais P. Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma. Nature 1980; 286: 533-5.
6. Paterlini-Brechot P, Saigo K, Murakami Y, et al. Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. Oncogene 2003; 22: 3911-6.
7. Horikawa I, Barrett JC. cis-Activation of the human telomerase gene (hTERT) by the hepatitis B virus genome. J Natl Cancer Inst 2001; 93: 1171-3.
8. Twu JS, Schloemer RH. Transcriptional trans-activating function of hepatitis B virus. J Virol 1987; 61: 3448-53.
9. Liu H, Shi W, Luan F, et al. Hepatitis B virus X protein upregulates transcriptional activation of human telomerase reverse transcriptase. Virus Genes 2010; 40: 174-82.
10. Luan F, Liu H, Gao L, et al. Hepatitis B virus protein preS2 potentially promotes HCC development via its transcriptional activation of hTERT. Gut 2009; 58: 1528-37.
11. Zhong S, Chan JY, Yeo W, Tam JS, Johnson PJ. Hepatitis B envelope protein mutants in human hepatocellular carcinoma tissues. J Viral Hepat 1999; 6: 195-202.
12. Hildt E, Munz B, Saher G, Reifenberg K, Hofschneider PH. The PreS2 activator MHBs(t) of hepatitis B virus activates c-raf-1/Erk2 signaling in transgenic mice. EMBO J 2002; 21: 525-35.
13. Fontenot JD, Rasmussen JP, Williams LM, et al. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005; 22: 329-41.
14. Sakaguchi S. Naturally arising Foxp3-expressing CD25 + CD4 + regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005; 6: 345-52.
15. Fontenot JD, Rudensky AY. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol 2005; 6: 331-7.
16. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-9.
17. Roux S, Apetoh L, Chalmin F, et al. CD4+CD25+ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer. J Clin Invest 2008; 118: 3751-61.
18. Ghiringhelli F, Menard C, Martin F, Zitvogel L. The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol Rev 2006; 214: 229-38.
19. Kobayashi N, Hiraoka N, Yamagami W, et al. FOXP3 + regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 2007; 13: 902-11.
20. Martin F, Ladoire S, Mignot G, Apetoh L, Ghiringhelli F. Human FOXP3 and cancer. Oncogene 2010; 29: 4121-9.
21. Zuo T, Wang L, Morrison C, et al. FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell 2007; 129: 1275-86.
22. Zuo T, Liu R, Zhang H, et al. FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2. J Clin Invest 2007; 117: 3765-73.
23. Ebert LM, Tan BS, Browning J, et al. The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells. Cancer Res 2008; 68: 3001-9.
24. Hinz S, Pagerols-Raluy L, Oberg HH, et al. Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res 2007; 67: 8344-50.
25. Wang WH, Jiang CL, Yan W, et al. FOXP3 expression and clinical characteristics of hepatocellular carcinoma. World J Gastroenterol 2010; 16: 5502-9.
26. Han CP, Lee MY, Tzeng SL, et al. Nuclear receptor interaction protein (NRIP) expression assay using human tissue microarray and immunohistochemistry technology confirming nuclear localization. J Exp Clin Cancer Res 2008; 27: 25.
27. Kamoi S, AlJuboury MI, Akin MR, Silverberg SG. Immunohistochemical staining in the distinction between primary endometrial and endocervical adenocarcinomas: another viewpoint. Int J Gynecol Pathol 2002; 21: 217-23.
28. Mantel PY, Ouaked N, Ruckert B, et al. Molecular mechanisms underlying FOXP3 induction in human T cells. J Immunol 2006; 176: 3593-602.
29. Liu H, Luan F, Ju Y, et al. In vitro transfection of the hepatitis B virus PreS2 gene into the human hepatocarcinoma cell line HepG2 induces upregulation of human telomerase reverse transcriptase. Biochem Biophys Res Commun 2007; 355: 379-84.
30. Du J, Liang X, Liu Y, et al. Hepatitis B virus core protein inhibits TRAIL-induced apoptosis of hepatocytes by blocking DR5 expression. Cell Death Differ 2009; 16: 219-29.
31. Hassan MM, Hwang LY, Hatten CJ, et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002; 36: 1206-13.
32. Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168-74.
33. Schluter V, Meyer M, Hofschneider PH, Koshy R, Caselmann WH. Integrated hepatitis B virus X and 3′ truncated preS/S sequences derived from human hepatomas encode functionally active transactivators. Oncogene 1994; 9: 3335-44.
34. Hildt E, Saher G, Bruss V, Hofschneider PH. The hepatitis B virus large surface protein (LHBs) is a transcriptional activator. Virology 1996; 225: 235-9.
35. Hildt E, Urban S, Hofschneider PH. Characterization of essential domains for the functionality of the MHBst transcriptional activator and identification of a minimal MHBst activator. Oncogene 1995; 11: 2055-66.
36. Lauer U, Weiss L, Lipp M, Hofschneider PH, Kekule AS. The hepatitis B virus preS2/St transactivator utilizes AP-1 and other transcription factors for transactivation. Hepatology 1994; 19: 23-31.